CELL & GENE COLLABORATIVE BLOG
Anna Rose Welch
Click here to e-mail Anna Rose
Anna Rose Welch is the director of Cell & Gene Collaborative. In this role, she is forging close relationships with the leading voices and organizations in the cell and gene therapy manufacturing sphere. This includes establishing a peer group comprising Cell & Gene company manufacturing SMEs, conducting interviews and hosting interactive roundtables on the evolving manufacturing paradigm, and authoring thought leadership articles and blog posts via the Cell & Gene Collaborative blog.
Prior to launching Cell & Gene Collaborative, Anna Rose spent five years building an extensive network and editorial following as the Chief Editor of Biosimilar Development. In addition to penning thought leadership on biosimilar regulatory affairs, government policy, and commercialization advances, she was also an active participant in the biosimilar conferences circuit. She was appointed chair or served as a speaker and panel moderator at international conferences, including the World Biosimilar Congress USA, The Biotech Pharma Summit (EU), the CBI Biosimilars Summit, DIA Biosimilars Conference, and the Biosimilar Medicines Group Conference (EU). In 2018, she was invited to Brazil where she addressed members of the Brazilian Ministry of Health, ANVISA, and local biologics and biosimilar manufacturers on establishing national biologics and biosimilar policies. She also represented the publication on a media tour of Bangkok, Thailand in 2017, during which she reported on the country’s efforts to bolster its life sciences industry. In addition to writing for Biosimilar Development, she penned the introductory chapter to the book, Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (Springer, 2018).
In 2018, her first book of poetry, We, The Almighty Fires, was published by Alice James Books.
ARCHIVED ARTICLES
- ARW’s Cell & Gene + RNA Manufacturing Must-Reads (Mac & Cheese Edition!)
- What Playing RISK Can Teach Us About mRNA Manufacturing
- Bluebird Bio FDA AdCom: 3 Key Takeaways For The Cell & Gene Therapy Industry
- ARW’s Cell & Gene Manufacturing Must-Reads (Asteroid Day Edition!)
- Bluebird Bio FDA AdCom: For Cell & Gene Manufacturing, FDA Approval Is Just One Of Many Milestones
- Bluebird Bio FDA AdCom: Your Viral Vector’s Future Is In The Eye Of The Beholder
- Bluebird Bio AdCom: Risk Vs. Benefit A “Living” Measurement For Commercialized CGTs
- From Manufacturing To C-Suite: “Scaling Up” C&G Therapy Communication
- ARW’s C&G+RNA Manufacturing Must-Reads (Capture The Flag Edition!)
- The “Renaissance” Approach To Cell & Gene Therapy Manufacturing